Biomarin Pharmaceutical (BMRN) Debt to Equity (2016 - 2024)
Historic Debt to Equity for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q2 2024 value amounting to $0.09.
- Biomarin Pharmaceutical's Debt to Equity changed N/A to $0.09 in Q2 2024 from the same period last year, while for Jun 2024 it was $0.09, marking a year-over-year change of. This contributed to the annual value of $0.1 for FY2023, which is 278306.19% up from last year.
- Latest data reveals that Biomarin Pharmaceutical reported Debt to Equity of $0.09 as of Q2 2024.
- In the past 5 years, Biomarin Pharmaceutical's Debt to Equity registered a high of $0.11 during Q2 2020, and its lowest value of $0.0 during Q4 2022.
- In the last 5 years, Biomarin Pharmaceutical's Debt to Equity had a median value of $0.01 in 2022 and averaged $0.05.
- In the last 5 years, Biomarin Pharmaceutical's Debt to Equity surged by 331096.17% in 2020 and then tumbled by 9344.62% in 2021.
- Biomarin Pharmaceutical's Debt to Equity (Quarter) stood at $0.09 in 2020, then plummeted by 87.75% to $0.01 in 2021, then plummeted by 69.4% to $0.0 in 2022, then skyrocketed by 2783.06% to $0.1 in 2023, then decreased by 6.15% to $0.09 in 2024.
- Its Debt to Equity stands at $0.09 for Q2 2024, versus $0.1 for Q1 2024 and $0.1 for Q4 2023.